Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lineage Cell Therapeutics (LCTX) Profit After Tax: 2009-2024

Historic Profit After Tax for Lineage Cell Therapeutics (LCTX) over the last 16 years, with Dec 2024 value amounting to -$18.6 million.

  • Lineage Cell Therapeutics' Profit After Tax fell 881.58% to -$29.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$67.7 million, marking a year-over-year decrease of 235.95%. This contributed to the annual value of -$18.6 million for FY2024, which is 13.39% up from last year.
  • Per Lineage Cell Therapeutics' latest filing, its Profit After Tax stood at -$18.6 million for FY2024, which was up 13.39% from -$21.5 million recorded in FY2023.
  • In the past 5 years, Lineage Cell Therapeutics' Profit After Tax ranged from a high of -$18.6 million in FY2024 and a low of -$43.3 million during FY2021.
  • Over the past 3 years, Lineage Cell Therapeutics' median Profit After Tax value was -$21.5 million (recorded in 2023), while the average stood at -$22.1 million.
  • Its Profit After Tax has fluctuated over the past 5 years, first crashed by 109.19% in 2021, then spiked by 39.10% in 2022.
  • Yearly analysis of 5 years shows Lineage Cell Therapeutics' Profit After Tax stood at -$20.7 million in 2020, then plummeted by 109.19% to -$43.3 million in 2021, then skyrocketed by 39.10% to -$26.4 million in 2022, then climbed by 18.47% to -$21.5 million in 2023, then climbed by 13.39% to -$18.6 million in 2024.